Extension application* assessment timetables
|
|
|
- Silvia King
- 5 years ago
- Views:
Transcription
1 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union 31 October 2017 EMA/412809/2015 Rev.2 Human Medicines Evaluation The timetables in this document may be subject to revision Extension application* assessment timetables Assessment of initial submission (120-day timetable) Assessment of responses to List of Questions (60-day timetable after clock-stop for submission of responses) Assessment of responses to List of Outstanding Issues (30-day timetable after clock-stop for responses) Assessment of responses to List of Outstanding Issues (30-day timetable after immediate responses) *These are also known as Annex I (of Regulation EC No 1234/2008) applications. European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 1 / 13
2 Assessment of initial submission (120-day timetable) Deadline for Start date (^) (Co) ARs from (~) from Draft LoQ List of Questions (LoQ) or A1 02/01/ /01/ /04/ /04/ /04/ /04/ /04/ /05/ /05/ /05/2017 A2 06/02/ /02/ /05/ /05/ /05/ /06/ /06/ /06/ /06/ /06/2017 A3 06/03/ /03/ /06/ /06/ /06/ /06/ /06/ /07/ /07/ /07/2017 A4 A5 27/04/ /05/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/2017 A6 24/05/ /06/ /09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/2017 A7 26/06/ /07/ /09/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2017 A8 31/07/ /08/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/2017 A9 11/09/ /09/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2018 A10 09/10/ /10/ /01/ /01/ /01/ /02/ /02/ /02/ /02/ /02/2018 A11 06/11/ /11/ /02/ /02/ /02/ /03/ /03/ /03/ /03/ /03/2018 A12 27/11/ /12/ /03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/2018 A13 15/01/ /02/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2018 A14 12/02/ /03/ /05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/2018 A15 08/03/ /03/ /06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/2018 A16 A17 30/04/ /05/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/2018 A18 04/06/ /06/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2018 A19 02/07/ /07/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2018 A20 30/07/ /08/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/2018 A21 17/09/ /10/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2019 A22 15/10/ /11/ /01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/2019 A23 12/11/ /11/ /02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2019 A24 26/11/ /12/ /03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/2019 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 2 / 13
3 Start date (^) (Co) ARs from (~) from Draft LoQ List of Questions (LoQ) or A25 14/01/ /01/ /04/ /04/ /05/ /05/ /05/ /05/ /05/ /05/2019 A26 11/02/ /02/ /05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/2019 A27 11/03/ /03/ /06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/2019 A28 A29 06/05/ /05/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/2019 A30 03/06/ /06/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2019 A31 01/07/ /07/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2019 A33 29/07/ /08/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/2019 A34 16/09/ /10/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2020 A35 14/10/ /10/ /01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/2020 A36 11/11/ /11/ /02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2020 A37 25/11/ /01/ /03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/2020 A38 13/01/ /01/ /04/ /04/ /05/ /05/ /05/ /05/ /05/ /05/2020 A39 10/02/ /02/ /05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/2020 A40 09/03/ /03/ /06/ /06/ /06/ /07/ /07/ /07/ /07/ /07/2020 A41 A42 04/05/ /05/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/2020 A43 01/06/ /06/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2020 A45 29/06/ /07/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2020 A46 27/07/ /08/ /11/ /11/ /11/ /11/ /11/ /11/ /11/ /12/2020 A47 14/09/ /10/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2021 A48 12/10/ /10/ /01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/2021 A49 09/11/ /11/ /02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2021 A50 23/11/ /12/ /03/ /03/ /03/ /03/ /03/ /04/ /04/ /04/2021 A51 04/01/ /01/ /04/ /04/ /04/ /04/ /04/ /05/ /05/ /05/2021 A52 08/02/ /02/ /05/ /05/ /05/ /06/ /06/ /06/ /06/ /06/2021 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 3 / 13
4 Start date (^) (Co) ARs from (~) from Draft LoQ List of Questions (LoQ) or A53 08/03/ /03/ /06/ /06/ /06/ /07/ /07/ /07/ /07/ /07/2021 A54 A55 30/04/ /05/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/2021 A56 31/05/ /06/ /09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/2021 A57 28/06/ /07/ /10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/2021 A58 02/08/ /08/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2021 The Agency strongly recommends submitting the application before the published submission deadline. This is to avoid missing the target start date as a result of a technically invalid ectd submission, in which case the submission is considered void and it needs to be re-despatched. (^) The validation period between submission date and start date is generally seventeen calendar days. For further information about the dates on which the Agency will be closed during the current year, please refer to the business hours and holidays page on the website. The Co- is involved only in case the extension application is submitted in support of an extension of indication. (~) Step applicable only if RMP is submitted. from and members and the draft List of Questions are not made available to MAHs. European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 4 / 13
5 Assessment of responses to List of Questions (LOQ) 60-day timetable after clock-stop for submission of responses Deadline for (s Joint) AR (^) (s Joint) from (~) from (s Joint) AR List of Outstanding Issues (LoOI) or B1 20/01/ /01/ /02/ /02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2017 B2 17/02/ /02/ /03/ /03/ /03/ /03/ /03/ /04/ /04/ /04/ /04/2017 B3 17/03/ /03/ /04/ /04/ /04/ /04/ /04/ /05/ /05/ /05/ /05/2017 B4 21/04/ /04/ /05/ /05/ /05/ /05/ /06/ /06/ /06/ /06/ /06/2017 B5 19/05/ /05/ /06/ /06/ /06/ /06/ /06/ /07/ /07/ /07/ /07/2017 B6 B7 14/07/ /07/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2017 B8 11/08/ /08/ /09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2017 B9 08/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2017 B10 13/10/ /10/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2017 B11 24/11/ /11/ /01/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2018 B12 22/12/ /12/ /01/ /01/ /01/ /01/ /02/ /02/ /02/ /02/ /02/2018 B13 19/01/ /01/ /02/ /02/ /02/ /02/ /03/ /03/ /03/ /03/ /03/2018 B14 23/02/ /02/ /04/ /03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/2018 B15 28/03/ /04/ /05/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2018 B16 27/04/ /04/ /06/ /05/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2018 B17 25/05/ /05/ /07/ /06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/2018 B18 B19 20/07/ /07/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2018 B20 17/08/ /08/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/2018 B21 14/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2018 B22 12/10/ /10/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2018 B23 30/11/ /12/ /01/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2019 B24 21/12/ /12/ /02/ /01/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2019 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 5 / 13
6 (s Joint) AR (^) (s Joint) from (~) from (s Joint) AR List of Outstanding Issues (LoOI) or B25 25/01/ /01/ /03/ /02/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2019 B26 22/02/ /02/ /04/ /03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/2019 B27 29/03/ /03/ /05/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2019 B28 26/04/ /04/ /06/ /05/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2019 B29 24/05/ /05/ /07/ /06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/2019 B30 B31 19/07/ /07/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2019 B32 16/08/ /08/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/2019 B33 13/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2019 B34 11/10/ /10/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2019 B35 29/11/ /12/ /01/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2020 B36 23/12/ /12/ /02/ /01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/2020 B37 24/01/ /01/ /03/ /02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2020 B38 28/02/ /03/ /04/ /03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2020 B39 27/03/ /03/ /05/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2020 B40 24/04/ /04/ /06/ /05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/2020 B41 22/05/ /05/ /06/ /06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/2020 B42 B43 17/07/ /07/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2020 B44 14/08/ /08/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/2020 B45 11/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2020 B46 09/10/ /10/ /11/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/2020 B47 27/11/ /11/ /01/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2021 B48 23/12/ /12/ /02/ /01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/2021 B49 22/01/ /01/ /03/ /02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2021 B50 19/02/ /02/ /03/ /03/ /03/ /03/ /03/ /04/ /04/ /04/ /04/2021 B51 19/03/ /03/ /04/ /04/ /04/ /04/ /04/ /05/ /05/ /05/ /05/2021 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 6 / 13
7 (s Joint) AR (^) (s Joint) from (~) from (s Joint) AR List of Outstanding Issues (LoOI) or B52 23/04/ /04/ /05/ /05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/2021 B53 21/05/ /05/ /06/ /06/ /06/ /06/ /07/ /07/ /07/ /07/ /07/2021 B54 B55 16/07/ /07/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2021 B56 13/08/ /08/ /09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2021 B57 10/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2021 B58 15/10/ /10/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/ /12/2021 B59 15/10/ /10/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/ /12/2021 The Agency strongly recommends submitting the application before the published submission deadline. This is to avoid missing the target start date as a result of a technically invalid ectd submission, in which case the submission is considered void and it needs to be re-despatched. (^) Step applicable if no RMP is submitted (no involvement). A Joint assessment report is circulated by the and Co- in case both are involved in the assessment (extension application in support of extension of indication). (~) Step applicable only if RMP is submitted. from and members are not made available to MAHs. European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 7 / 13
8 Assessment of responses to List of Outstanding Issues (LoOI) 30-day timetable after clock-stop for responses Deadline for (s from (~) from (s C1 24/01/ /01/ /02/ /01/ /02/ /02/ /02/ /02/ /02/ /02/2017 C2 21/02/ /02/ /03/ /02/ /03/ /03/ /03/ /03/ /03/ /03/2017 C3 22/03/ /03/ /04/ /03/ /03/ /03/ /04/ /04/ /04/ /04/2017 C4 18/04/ /04/ /05/ /04/ /04/ /04/ /05/ /05/ /05/ /05/2017 C5 23/05/ /05/ /06/ /05/ /05/ /06/ /06/ /06/ /06/ /06/2017 C6 20/06/ /06/ /07/ /06/ /06/ /06/ /07/ /07/ /07/ /07/2017 C7 C8 15/08/ /08/ /08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2017 C9 12/09/ /09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2017 C10 10/10/ /10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/2017 C11 14/11/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2017 C12 22/12/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2018 C13 23/01/ /01/ /02/ /01/ /01/ /02/ /02/ /02/ /02/ /02/2018 C14 20/02/ /02/ /03/ /02/ /02/ /03/ /03/ /03/ /03/ /03/2018 C15 27/03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2018 C16 30/04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2018 C17 29/05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2018 C18 26/06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2018 C19 C20 21/08/ /08/ /09/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2018 C21 18/09/ /09/ /10/ /09/ /09/ /09/ /10/ /10/ /10/ /10/2018 C22 16/10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2018 C23 13/11/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2018 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 8 / 13
9 (s from (~) from (s C24 21/12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2019 C25 29/01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2019 C26 26/02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2019 C27 27/03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2019 C28 29/04/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2019 C29 28/05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2019 C30 25/06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2019 C31 C32 20/08/ /08/ /09/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2019 C33 17/09/ /09/ /10/ /09/ /09/ /09/ /10/ /10/ /10/ /10/2019 C34 15/10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2019 C35 12/11/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/ /12/2019 C36 23/12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2020 C37 28/01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2020 C38 25/02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2020 C39 31/03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2020 C40 28/04/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2020 C41 26/05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2020 C42 23/06/ /06/ /07/ /06/ /07/ /07/ /07/ /07/ /07/ /07/2020 C43 C44 18/08/ /08/ /09/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2020 C45 15/09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/2020 C46 13/10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2020 C47 10/11/ /11/ /11/ /11/ /11/ /11/ /11/ /11/ /12/ /12/2020 C48 23/12/ /12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2021 C49 26/01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2021 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 9 / 13
10 (s from (~) from (s C50 23/02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2021 C51 23/03/ /03/ /04/ /03/ /03/ /03/ /04/ /04/ /04/ /04/2021 C52 20/04/ /04/ /05/ /04/ /04/ /04/ /05/ /05/ /05/ /05/2021 C53 25/05/ /05/ /06/ /05/ /06/ /06/ /06/ /06/ /06/ /06/2021 C54 22/06/ /06/ /07/ /06/ /06/ /07/ /07/ /07/ /07/ /07/2021 C55 C56 17/08/ /08/ /09/ /08/ /08/ /08/ /09/ /09/ /09/ /09/2021 C57 14/09/ /09/ /09/ /09/ /09/ /09/ /09/ /10/ /10/ /10/2021 C58 12/10/ /10/ /10/ /10/ /10/ /10/ /10/ /11/ /11/ /11/2021 C59 16/11/ /11/ /12/ /11/ /11/ /11/ /12/ /12/ /12/ /12/2021 The Agency strongly recommends submitting the application before the published submission deadline. This is to avoid missing the target start date as a result of a technically invalid ectd submission, in which case the submission is considered void and it needs to be re-despatched. A Joint assessment report is circulated by the and Co- in case both are involved in the assessment (extension application in support of extension of indication). (~) Step applicable only if RMP is submitted. from and members are not made available to MAHs. European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 10 / 13
11 Assessment of responses to List of Outstanding Issues (LoOI) 30-day timetable after immediate responses Deadline for (s from (~) (##) from (s D1 31/01/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2017 D2 28/02/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2017 D3 29/03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2017 D4 25/04/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2017 D5 23/05/ /05/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2017 D6 27/06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2017 D7 D8 15/08/ /08/ /08/ /08/ /09/ /09/ /09/ /09/ /09/2017 D9 19/09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/ /10/2017 D10 17/10/ /10/ /10/ /10/ /10/ /11/ /10/ /11/ /11/2017 D11 14/11/ /11/ /11/ /11/ /12/ /12/ /12/ /12/ /12/2017 D12 19/12/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2018 D13 30/01/ /01/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2018 D14 27/02/ /02/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2018 D15 27/03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2018 D16 30/04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2018 D17 05/06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2018 D18 03/07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2018 D19 D20 21/08/ /08/ /09/ /09/ /09/ /09/ /09/ /09/ /09/2018 D21 25/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /10/2018 D22 23/10/ /10/ /10/ /10/ /11/ /11/ /11/ /11/ /11/2018 D23 20/11/ /11/ /11/ /11/ /12/ /12/ /12/ /12/ /12/2018 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 11 / 13
12 (s from (~) (##) from (s D24 08/01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2019 D25 05/02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2019 D26 05/03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2019 D27 03/04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2019 D28 06/05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2019 D29 04/06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2019 D30 02/07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2019 D31 D32 27/08/ /08/ /09/ /09/ /09/ /09/ /09/ /09/ /09/2019 D33 24/09/ /09/ /10/ /10/ /10/ /10/ /10/ /10/ /10/2019 D34 22/10/ /10/ /10/ /10/ /11/ /11/ /11/ /11/ /11/2019 D35 19/11/ /11/ /11/ /11/ /12/ /12/ /12/ /12/ /12/2019 D36 07/01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2020 D37 04/02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2020 D38 03/03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2020 D39 07/04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2020 D40 05/05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2020 D41 02/06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2020 D42 30/06/ /07/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2020 D43 D44 25/08/ /08/ /09/ /09/ /09/ /09/ /09/ /09/ /09/2020 D45 22/09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/ /10/2020 D46 20/10/ /10/ /10/ /10/ /11/ /11/ /11/ /11/ /11/2020 D47 17/11/ /11/ /11/ /11/ /11/ /12/ /11/ /12/ /12/2020 D48 05/01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/ /01/2021 D49 02/02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/ /02/2021 European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 12 / 13
13 (s from (~) (##) from (s D50 02/03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/ /03/2021 D51 30/03/ /03/ /04/ /04/ /04/ /04/ /04/ /04/ /04/2021 D52 27/04/ /04/ /05/ /05/ /05/ /05/ /05/ /05/ /05/2021 D53 01/06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/ /06/2021 D54 29/06/ /06/ /07/ /07/ /07/ /07/ /07/ /07/ /07/2021 D55 D56 24/08/ /08/ /09/ /09/ /09/ /09/ /09/ /09/ /09/2021 D57 21/09/ /09/ /09/ /09/ /10/ /10/ /10/ /10/ /10/2021 D58 19/10/ /10/ /10/ /10/ /11/ /11/ /11/ /11/ /11/2021 D59 23/11/ /11/ /12/ /12/ /12/ /12/ /12/ /12/ /12/2021 ( ) This timetable is only used exceptionally and after agreement with the s when minor issues remain which allow the applicant to respond shortly after the list of questions and the s to assess the responses within a shortened assessment time. The Agency strongly recommends submitting the application before the published submission deadline. This is to avoid missing the target start date as a result of a technically invalid ectd submission, in which case the submission is considered void and it needs to be re-despatched. A Joint assessment report is circulated by the and Co- in case both are involved in the assessment (extension application in support of extension of indication). (~) Step applicable only if RMP is submitted. (##) A discussion is not foreseen in this timetable; member comments are reflected in the updated assessment report. from and members are not made available to Applicants. European Medicines Agency, Reproduction is authorised provided the source is acknowledged. Page 13 / 13
Informed consent and multiple application*
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
Safety Signal - Assessment of responses to Request for Supplementary Information (RSI)
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
EMA Technical Anonymisation Group (TAG)
EMA Technical Anonymisation Group (TAG) Call for applications Presented by Monica Dias, PhD Policy and Crisis Coordinating Officer An agency of the European Union TAG Anonymisation Background The Agency
Enpr EMA. Enpr-EMA. European Network of Paediatric Research at the European Medicines Agency
Enpr EMA European Network of Paediatric Research at the European Medicines Agency Enpr-EMA European Network of Paediatric Research at the European Medicines Agency An agency of the European Union Enpr
Guidance on the anonymisation of clinical reports for the purpose of publication
Guidance on the anonymisation of clinical reports for the purpose of publication Stakeholder meeting 6 July 2015, London Presented by Monica Dias Policy Officer An agency of the European Union Scope and
How Paediatric Research Networks can help drug development
How Paediatric Research Networks can help drug development Mark Turner An agency of the European Union Why networks? Significant increase in trials and participants Delays are now significant Networks
MA/INS/GMP/735037/2014 Annex 1 of the GMP Guidelines on Good Manufacturing Practice - Manufacture of Sterile Medicinal Products
31 March, 2015 European Medicines Agency GMP/GDP Inspectors Working Group (GMP/GDP IWG) 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Subject: MA/INS/GMP/735037/2014 Annex 1 of the GMP
Submission of comments on Review of the Variations Guidelines (EC 1234/2008)
12 July 2012 Submission of comments on Review of the Variations Guidelines (EC 1234/2008) Comments from: Name of organisation or individual Leem Please note that these comments and the identity of the
ENCePP Work Plan
EMA/150117/2014 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP
EU s Innovative Medical Technology and EMA s Measures
EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency
Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2017
17 July 2018 EMA/INS/GMP/19273/2018 Committees and Inspections Annual report of the Good Manufacturing and Distribution Practice Inspectors Working 30 Churchill Place Canary Wharf London E14 5EU United
Towards a 21 st Century Regulator s role EMA Early Access Toolbox
Towards a 21 st Century Regulator s role EMA Early Access Toolbox Bulgarian Presidency Conference on Health as the Real Winner: Presidency Conference on Options to Provide Better Medicines for All 6 March
Pre- and post-authorisation regulatory support for SMEs
25 March 2013 EMA/214813/2013 Human Medicines Development and Evaluation Pre- and post-authorisation regulatory support for SMEs 26 April 2013 European Medicines Agency, London, United Kingdom 7 Westferry
12808/16 PG/cb 1 DG G 3 C
Council of the European Union Brussels, 30 September 2016 (OR. en) 12808/16 ESPACE 46 RECH 283 COMPET 515 TRANS 368 TELECOM 184 'I/A' ITEM NOTE From: To: Subject: General Secretariat of the Council Permanent
Agenda Industry stakeholder platform on research and development support
20 April 2017 EMA/88749/2017 Agenda Industry stakeholder platform on research and development support 25 April 2017 10:00 16:30, Meeting room 03-F Chair: Michael Berntgen Item Agenda Time 1. Welcome /
Final Minutes of EMA/EUnetHTA meeting
4 June 2013 EMA/297283/2013 14 May 2013 chaired by Hans-Georg Eichler and Finn Børlum Kristensen Role Chairs Participants Name Hans-Georg Eichler and Finn Børlum Kristensen EMA: Peter Arlett, Michael Berntgen,
ENCePP Work Plan
EMA/231507/2012 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP
EMA/EC multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation
20 March 2016 EMA/49414/2018 Human Medicines Research and Development Support Division EMA/EC multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation 20 March 2018
RADIO SPECTRUM POLICY GROUP. Commission activities related to radio spectrum policy
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Group RSPG Secretariat Brussels, 05 June
Pharmacovigilance System - EU
Pharmacovigilance System - EU Rechtsanwalt Prof. Burkhard Sträter Sträter Rechtsanwälte Kronprinzenstraße 20 Fon: +49 (0) 228-934 54-0 mail@straeterlawyers.de D-53173 Bonn Fax: +49 (0) 228-934 54-54 Pharmacovigilance
RADIO SPECTRUM POLICY GROUP. Commission activities related to radio spectrum policy
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Group RSPG Secretariat Brussels, 03 October
INTERNATIONAL TELECOMMUNICATION UNION
参考資料 2 INTERNATIONAL TELECOMMUNICATION UNION Radiocommunication Bureau (Direct Fax N. +41 22 730 57 85) Administrative Circular CACE/564 22 March 2012 To Administrations of Member States of the ITU, Radiocommunication
Office for Nuclear Regulation
Office for Nuclear Regulation Redgrave Court Merton Road Bootle Merseyside L20 7HS www.hse.gov.uk/nuclear PROJECT ASSESSMENT REPORT Report Identifier: ONR-Policy-all-PAR-11-001 Revision: 2 Project: Implementation
(Non-legislative acts) REGULATIONS
19.11.2013 Official Journal of the European Union L 309/1 II (Non-legislative acts) REGULATIONS COMMISSION DELEGATED REGULATION (EU) No 1159/2013 of 12 July 2013 supplementing Regulation (EU) No 911/2010
Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation
Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process
REACH Authorisation Application for authorisation: Key issues for applicants and outlook for 2013
REACH Authorisation Application for authorisation: Key issues for applicants and outlook for 2013 Workshop on Airworthiness and REACH Authorisation Cologne 23 January 2013 Matti Vainio, ECHA - Head of
List of nationally authorised medicinal products
17 March 2016 EMA/346191/2016 Procedure Management and Committees Support Active substance: ethinylestradiol / gestodene (transdermal application) Procedure no.: PSUSA/00010145/201508 30 Churchill Place
Institute for Health and Consumer Protection 2007
GMOREGEX User Guide A. Rana, F. Foscarini, M. Canonico Institute for Health and Consumer Protection 2007 EUR 22653 EN The mission of the Institute for Health and Consumer Protection is to provide scientific
EUROPEAN CENTRAL BANK
25.11.2009 Official Journal of the European Union C 284/1 I (Resolutions, recommendations and opinions) OPINIONS EUROPEAN CENTRAL BANK OPINION OF THE EUROPEAN CENTRAL BANK of 5 November 2009 on recommendations
RADIO SPECTRUM POLICY GROUP. Commission activities related to radio spectrum policy
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Group RSPG Secretariat Brussels, 24 February
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
MEASURES TO INCREASE THE EFFICIENCY OF CIF COMMITTEES. CTF-SCF/TFC.11/7/Rev.1 January 27, 2014
MEASURES TO INCREASE THE EFFICIENCY OF CIF COMMITTEES CTF-SCF/TFC.11/7/Rev.1 January 27, 2014 I. INTRODUCTION 1. At the May 2013 CIF Committee meetings, the CIF Administrative Unit was requested to give
MSc in Engineering (Technology Based Business Development) study programme Weekly schedule, autumn semester 2014
MSc in (Technology Based Business Development) study programme Weekly schedule, autumn semester 2014 (Mondays and Tuesdays) Programme 01.09 Monday 1 02.09 Tuesday 03.09 Wednesday 04.09 Thursday Visits
Important information on the further use of passivating agents with Cr(VI) content
Important information on the further use of passivating agents with Cr(VI) content The approval procedure for chromium trioxide (CrO 3 ) and the ensuing acids (including oligomers) in accordance with EC
THE PLANNING PROCEDURE FOR HF BROADCASTING - ARTICLE 12 OF THE RADIO REGULATIONS
THE PLANNING PROCEDURE FOR HF BROADCASTING - ARTICLE 12 OF THE RADIO REGULATIONS Nedialko Miltchev Radiocommunication Bureau 1 Introduction The current procedures for the use of the HF bands allocated
Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
Pharmacovigilance Inspection Metrics Report
April 2013 - March 2014 Pharmacovigilance Inspection Metrics Report Introduction During the period 01 April 2013 to 31 March 2014, the Pharmacovigilance inspectorate conducted 56 inspections of Marketing
IR UK Interface Requirement 2095 High Duty Cycle Network Relay Points (NRPs)
IR 2095 - UK Interface Requirement 2095 High Duty Cycle Network Relay Points (NRPs) Publication date: January 2015 Date amended: January 2018 2015/1535/EU Notification number: 2014/0480/UK Contents Section
RADIO SPECTRUM POLICY GROUP. 18 th Progress Report of the RSPG Working Group on cross-border coordination
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Group RSPG Secretariat Brussels, 5 June
Author Instructions FPIN Editorial Manager
Author Instructions FPIN Editorial Manager Login Information: www.editorialmanager.com/fpin Your username and password will have been sent to you by the FPIN Project Manager. If you do not have it, please
Regulation on medicinal products for paediatric use
Regulation on medicinal products for paediatric use ANWALTSKANZLEI STRÄTER Burkhard Sträter Kronprinzenstraße 20 53173 Bonn Tel.:++49-228 228-93454 93454-0 Fax.:++49-228 228-93454 93454-54 Mail@kanzleistraeter
Contents EUROPEAN UNION AGENCY FOR RAILWAYS. Accompanying Report Practical arrangements for safety certification ERA-REC-126/ACR V 1.
Contents 1. Executive summary... 3 2. Introduction... 4 2.1. Purpose and scope... 4 2.2. Background... 4 3. Workgroups... 5 4. Working method... 5 5. Content of the practical arrangements... 7 5.1. Objective...
ECC. Doc. ECC(08)038 CEPT. 20 th Meeting Kristiansand, June Date issued: 23 rd May Subject: Password protection required?
Doc. ECC(08)038 ECC Electronic Communications Committee CEPT 20 th Meeting Kristiansand, 23 27 June 2008 Date issued: 23 rd May 2008 Source: Subject: RSC TCAM/RSC RIG II Password protection required? (Y/N)
Publishing date: 22/12/2014 Document title: ACER Opinion on the draft ENTSO-E Work Programme We appreciate your feedback
Publishing date: 22/12/2014 Document title: ACER Opinion on the draft ENTSO-E Work Programme 2014-2015 We appreciate your feedback Please click on the icon to take a 5 online survey and provide your feedback
D1.10 SECOND ETHICAL REPORT
Project Acronym DiDIY Project Name Digital Do It Yourself Grant Agreement no. 644344 Start date of the project 01/01/2015 End date of the project 30/06/2017 Work Package producing the document WP1 Project
Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
MAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals
MAH Responsibilities including the Management of CMOs QP Forum 2017 - Workshop Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals 25 th April 2017 Alexion Pharmaceuticals in Ireland A
(Text with EEA relevance)
L 149/16 14.6.2018 COMMISSION IMPLEMTING REGULATION (EU) 2018/868 of 13 June 2018 amending Regulation (EU) No 1301/2014 and Regulation (EU) No 1302/2014 as regards provisions on energy measuring system
COMMISSION IMPLEMENTING DECISION. of XXX
EUROPEAN COMMISSION Brussels, XXX [ ](2018) XXX draft COMMISSION IMPLEMENTING DECISION of XXX on the harmonisation of radio spectrum for use by short range devices within the 874-876 and 915-921 MHz frequency
Highlight report of the 2 nd industry stakeholder platform on research and development support
5 January 2018 EMA/759581/2017 Human Medicines Research and Development Support Division Highlight report of the 2 nd industry stakeholder platform on research and development 15 November 2017 Role Chair:
Fellowship Applications
Suggestions for Prospective Graduate Students Michael Moody Harvey Mudd College Over the years I served many times on graduate admissions committees in two different departments. I have also reviewed many
ATMP GMP requirements. Andrew Hopkins
Andrew Hopkins Scope GMP for ATMPs Points to consider Survey MHRA next steps Questions 2 GMP for ATMPs The usual process for GMP updates Problem statement submitted to IWG and PIC/S Reviewed and if accepted
Planetary Protection for Human Exploration Missions
National Aeronautics and Space Administration Planetary Protection for Human Exploration Missions No D Bette Siegel, Ph.D. Human Exploration and Operations Directorate November 12, 2013 NASA Advisory Council
CBD Request to WIPO on the Interrelation of Access to Genetic Resources and Disclosure Requirements
CBD Request to WIPO on the Interrelation of Access to Genetic Resources and Disclosure Requirements Establishing an adequate framework for a WIPO Response 1 Table of Contents I. Introduction... 1 II. Supporting
Fact Sheet IP specificities in research for the benefit of SMEs
European IPR Helpdesk Fact Sheet IP specificities in research for the benefit of SMEs June 2015 1 Introduction... 1 1. Actions for the benefit of SMEs... 2 1.1 Research for SMEs... 2 1.2 Research for SME-Associations...
Publishing Tips. Submitting Your Article: Ways to Submit
Publishing Tips This information is intended to be an ongoing work-in-progress. We welcome comments and additions to this information. Please feel free to add your thoughts about the publishing process.
Intimate Communications Hub Interface Specification Report to Secretary of State
Intimate Communications Hub Interface Specification Report to Secretary of State DCC V1.0 28/02/14 Page 1 of 14 Executive Summary 1. DCC is required in accordance with the terms of its Licence to produce,
UK Interface Requirement 2044
UK Interface Requirement 2044 Business Radio Land Mobile Services, covering Business Radio (Area Defined), Business Radio (Technically Assigned) and Business Radio (Light Licence) Authorisations Published:
Guidance on the anonymisation of clinical reports for the purpose of publication in accordance with policy 0070
Guidance on the anonymisation of clinical reports for the purpose of publication in accordance with policy 0070 Stakeholder webinar 24 June 2015, London Presented by Monica Dias Policy Officer An agency
Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
Executive Consulting Report Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market November 2017 Francois Maignen, Mikel Berdud, Grace Hampson & Paula Lorgelly
ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
RADIO SPECTRUM COMMITTEE
Ref. Ares(2018)4780924-18/09/2018 EUROPEAN COMMISSION Communications Networks Content & Technology Directorate-General Electronic Communications Networks & Services Radio Spectrum Policy Brussels, 12 July
Update on Lessons Learned from the EMA-FDA QbD Pilot
Update on Lessons Learned from the EMA-FDA QbD Pilot IFPAC 2014 Annual Meeting 22 January 2014 Sharmista Chatterjee, Ph.D. CMC Lead for QbD, ONDQA/OPS/CDER/FDA Background One of the projected outcomes
Coping with Writer s Block. Writing is tough
Coping with Writer s Block Dr Jocalyn Clark Senior Editor, PLoS Medicine Consultant, Grand Challenges Canada February 2012 Writing is tough Even the best or most naturally gifted writers struggle with
Co-ordination of the Group of Notified Bodies for the Construction Products Directive 89/106/EEC. GNB-CPD Conference on CPR
GNB-CPD All Co-ordination of the Group of Notified Bodies for the Construction Products Directive 89/106/EEC NB-CPD/All-13/112 Issued: 13 June 2013 Answers to GNB- CPD questions GNB-CPD Conference on CPR
Airworthiness Directive
Airworthiness Directive AD No.: 2016-0018R1 Issued: 14 September 2016 EASA AD No.: 2016-0018R1 Note: This Airworthiness Directive (AD) is issued by EASA, acting in accordance with Regulation (EC) 216/2008
B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
RADIO SPECTRUM COMMITTEE
Ref. Ares(2017)1654881-28/03/2017 EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Brussels,
MONETARY AGREEMENT between the European Union and the Vatican City State (2010/C 28/05)
4.2.2010 Official Journal of the European Union C 28/13 MONETARY AGREEMENT between the European Union and the Vatican City State (2010/C 28/05) THE EUROPEAN UNION, represented by the European Commission
e-submission Quick Reference Guide for Economic Operators
e-submission Quick Reference Guide for Economic Operators e-submission Quick Guide for Economic Operators Page 1 Welcome to e-submission. This quick reference guide contains: Introduction to e-submission
Personal Medical Services (PMS) Contract Review Update
Personal Medical Services (PMS) Contract Review Update 1. Introduction NHS England commenced the Personal Medical Services (PMS) Review process across the North West London (NWL) Collaboration of CCGs
Position Paper.
Position Paper Brussels, 30 September 2010 ORGALIME OPINION ON THE POSITION OF THE COUNCIL AT FIRST READING WITH A VIEW TO THE ADOPTION OF A REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL LAYING
Radiocommunication Facility Review Protocol
Radiocommunication Facility Review Protocol 1.0 PURPOSE 1.1 The purpose of this protocol is to outline the guidelines and review process through which Radiocommunication Facilities are evaluated within
EUROPEAN CENTRAL BANK
C 273/2 Official Journal of the European Union 16.9.2011 III (Preparatory acts) EUROPEAN CENTRAL BANK EUROPEAN CENTRAL BANK OPINION OF THE EUROPEAN CENTRAL BANK of 23 August 2011 on a proposal for a Regulation
UPDATES to the. Rules of Procedure. (Edition of 1998) approved by the Radio Regulations Board. Contents
UPDATES to the Rules of Procedure (Edition of 1998) approved by the Radio Regulations Board Revision (1) (Circular No.) Date Part ARS Pages to be removed Pages to be inserted 1 June 1999 A1 ARS5 15-18
2020 Census Geographic Partnership Programs. Heidi Crawford Data Dissemination Specialist U.S. Census 1 Bureau
2017 Oregon Census Data Users Workshop September 20 &21, 2017 2020 Census Geographic Partnership Programs Heidi Crawford Data Dissemination Specialist U.S. Census 1 Bureau Geographic Partnership Opportunities
THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN
THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN www.laba-uk.com Response from Laboratory Animal Breeders Association to House of Lords Inquiry into the Revision of the Directive on the Protection
Scope. Interpretative provisions
MNB Decree No. 3/2010 (I. 28.) of the Governor of Magyar Nemzeti Bank on the reproductions of forint and euro coins In exercise of my powers under Article 60(1)(f), (g) and (i) of Act LVIII of 2001 on
Marine Strategy Framework Directive (MSFD) Common Implementation Strategy (CIS)
Marine Strategy Framework Directive (MSFD) Common Implementation Strategy (CIS) Summary MSFD CIS work plan for 2012/2014 and beyond (As agreed by Marine Directors 5 June 2012) This document sets out the
2020 Census Local Update of Census Addresses Operation (LUCA)
2020 Census Local Update of Census Addresses Operation (LUCA) The Decennial Census The purpose is to conduct a census of population and housing and disseminate results to the President, the States, and
Mobilisation and Mutual Learning (MML) Action Plans on Societal Challenges
KI-NA-24-837-EN-C E U R O P E A N COMMISSION Research & Innovation Science in Society You are a research organisation, a business or a civil society organisation ready to collaborate with other actors
IR UK Interface Requirement 2083
IR 2083 - UK Interface Requirement 2083 Hand-held Very High Frequency (VHF) radiotelephone equipment for the maritime mobile service operating in the VHF bands with integrated class D DSC (Digital Selective
Guidance for Industry and FDA Staff Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use
Guidance for Industry and FDA Staff Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use Document issued on: November 30, 2004 The draft of this document
ASD EUROSPACE RESEARCH AND TECHNOLOGY COMMITTEE (SRTC)
ASD EUROSPACE RESEARCH AND TECHNOLOGY COMMITTEE (SRTC) TERMS OF REFERENCE RT PANEL APPROVED 18/02/2011 GENERAL This document describes the terms of reference for the Space Research and Technology Committee
UNOFFICIAL TRANSLATION
Decree 34/2014. (IX. 25.) of the Governor of the Magyar Nemzeti Bank amending MNB Decree No. 11/2011 (IX. 6.) on the processing and distribution of banknotes and on technical tasks relating to the protection
Interaction btw. the GDPR and Clinical Trials Regulation
Interaction btw. the GDPR and Clinical Trials Marjut Salokannel SaReCo Oslo, Clinical Trials (CTR) approved in 2014 and will most likely come into effect as of Oct. 2018 all information btw. the parties
REPORT FROM THE COMMISSION. of TO THE ECONOMIC AND FINANCIAL COMMITTEE
EUROPEAN COMMISSION Brussels, 14.10.2015 C(2015) 6960 final REPORT FROM THE COMMISSION of 14.10.2015 TO THE ECONOMIC AND FINANCIAL COMMITTEE under Article 12(4) of Regulation (EU) No 1210/2010 of the European
Overview of the BPR and Authorisation procedures
Overview of the BPR and Authorisation procedures Biocides Symposium 2014 Bratislava, Slovakia 22-23 May 2014 M. Ludovic Chatelin European Commission DG Environment, Unit A.3 I Overview : key elements of
Working Party 5D LIAISON STATEMENT TO EXTERNAL ORGANIZATIONS ON THE SCHEDULE FOR UPDATING RECOMMENDATION ITU-R M.
Radiocommunication Study Groups 23rd Meeting of Working Party Beijing, China, 23 Feb. - 2 Mar. 2016 Attachment to Document /82 (not yet available) (Source: Document /TEMP/15(Rev.2)) 2 March 2016 English
SECTION SUBMITTAL PROCEDURES
SECTION 01330 - SUBMITTAL PROCEDURES PART 1 - GENERAL 1.1 RELATED DOCUMENTS A. Drawings and general provisions of the Contract, including General and Supplementary Conditions and other Division 1 Specification
RADIO SPECTRUM COMMITTEE
Ref. Ares(2018)3947109-25/07/2018 EUROPEAN COMMISSION Communications Networks Content & Technology Directorate-General Electronic Communications Networks & Services Spectrum Brussels, 12 July 2018 DG CONNECT/B4
European Commission Health and Consumers Directorate General, Brussels
PDA EUROPE Adalbertstr, 9 16548 Glienicke/Berlin Germany Tel: +49 33056 2377-0 or -10 Fax: +49 33056 2377-77 or -15 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
RADIO SPECTRUM COMMITTEE
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology Electronic Communications Networks and Services Radio Spectrum Policy Brussels, 08 June 2018 DG CONNECT/B4 RSCOM17-60rev3
This is an unofficial translation. The legally binding text is the original Czech version.
Prague 4 December 2012 Ref.: ČTÚ-176 487/2012-605 On the basis of public consultation under Section 130 of the Act No. 127/2005 Coll., on electronic communications and on amendment to certain related acts
CITES Scientific Authority The Netherlands
CC17/516 CITES Scientific Authority The Netherlands Reference: Imports of Galanthus woronowii bulbs exported by Georgia with source code A have been a topic of discussion for many years. The bulbs are
Implementation of Regulation (EC) No 1107/ State of affairs -
XIVth CEUREG Forum 7-8 October 2010, Brno Implementation of Regulation (EC) No 1107/2009 - State of affairs - Wolfgang Reinert Unit E.3 Chemicals, Contaminants and Pesticides Regulation (EC) No 1107/2009
FP7-INFRASTRUCTURES
FP7 Research Infrastructures Call for proposals FP7-INFRASTRUCTURES-2012-1 European Commission, DG Research, Unit B.3 FP7 Capacities Overall information Definition of Research Infrastructures The Research
UK Interface Requirements to IR
UK Interface Requirements 2015.1 to IR 2015.3 Spectrum Access in the 3400 MHz to 4009 MHz band Interface Requirement 2015/1535/EU Notification number Date IR 2015.1 2011/189/UK December 2011 IR 2015.2
WP197 Capacity Market Metering Test
WP197 Capacity Market Metering Test EMRS Working Practice Public Version: 4.0 Date: 20 July 2018 Table of Contents Change Amendment Record 4 1. Introduction 5 1.1 Scope and Purpose 5 1.2 Main Users and
SCOTTISH ENVIRONMENT PROTECTION AGENCY BOARD MEETING
SCOTTISH ENVIRONMENT PROTECTION AGENCY BOARD MEETING The one hundred and forty-fourth meeting of the Agency Board will take place at 1.00pm on Tuesday 26 July 2016 in the Board Room, Angus Smith Building,